More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Share on Pinterest A new study found that GLP1-RA medications may help lower the risk of a cardiovascular event in people with type 2 diabetes. Getty Images Researchers say GLP-1 drugs prescribed for ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to ...

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...

Share on Pinterest The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) ...

With class action lawsuits filed, these are the alleged side effects of GLP-1 drugs, like Ozempic, Wegovy and Mounjaro.